PS
TGTX icon

Principal Securities’s TG Therapeutics TGTX Stock Holding History

Principal Securities’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6
Closed -$217 – 3299
2025
Q3 		$217 Buy
+6
New +$198 ﹤0.01% 3641

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Principal Securities's TGTX Position: Q4 2025 in Review

Principal Securities sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 6 shares — an estimated $217 sold.

Principal Securities first reported a position in TGTX in Q3 2025 and held it in 1 quarter. The position peaked at $217 in Q3 2025. 352 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Principal Securities reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 6 TG Therapeutics shares in Q4 2025, an estimated $217.
  • Principal Securities first reported a position in TG Therapeutics in Q3 2025 and held it in 1 quarter.
  • Principal Securities's TG Therapeutics position peaked at $217 in Q3 2025.
  • 352 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.